Skip to main content
OpenTrials
Completed

NCT Number: NCT05045430

PMS Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds

Post Market Surveillance Study to confirm the safety and performance of Silver II Non-Woven Dressing in Chronic and Acute Wounds

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nianwi Healthcare, Germiston, South Africa

Loading trial locations.

About this study

The design of the study is an open-label, multicentre, single arm clinical trial in subjects with moderate to heavily exuding infected chronic and acute wounds consisting of Pressure ulcers, Leg ulcers, Diabetic ulcers, Post-operative surgical wounds, Graft and donor sites, Cavity wounds, Trauma wounds (dermal lesions, trauma injuries or incisions) and Superficial and partial thickness burns. The performance data from this study will support clinically meaningful rates of successful improvement in the signs and symptoms of infection, without re-infection during 6-week treatment and follow up period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females, age 18 years or above. (Females must not be pregnant and if of reproductive age should be using contraception).
  • Patients who are able to understand and give informed consent to take part in the study.
  • Have one or more of the following: Pressure ulcer, Leg ulcer, Diabetic ulcers, Post-operative surgical wounds, Graft and donor sites, Cavity wounds, Trauma wounds (dermal lesions, trauma injuries or incisions) and superficial and partial thickness burn wounds that are infected, or are at high risk of infection , that are moderate to heavy levels of exudate.
  • For Partial Thickness Second Degree Burns that require grafting - only those grafts with single thickness mesh grafts that have X % epithelialization will be enrolled [Note: % epithelization to be added once sites/countries are chosen as this is specific to the territory where the Silver II Non Woven Dressing study is likely to be performed].

Exclusion criteria

  • Patients who are known to be non-compliant with medical treatment,
  • Patients who are known to be sensitive to any of the device components
  • Subject is pregnant or actively breastfeeding;
  • Subject has a known sensitivity to Silver;
  • Life expectancy of <6 months;
  • Maximum burn area of > 20% total body area. Using the rule of nines assessment tool. [Note: criteria to be confirmed once sites/countries are chosen]
  • Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study;

Treatment and study plan

Silver II Non-Woven Dressing

Device

Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.

Subjects will be evaluated as follows:

Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.

The assessment of the presence and reduction of the signs and symptoms of Infection.

Primary outcomes

  1. Effectiveness of the Silver II Non-Woven Dressing

    Time frame: No worsening of any signs/ symptoms of infection at 6 weeks or if infection resolved prior to 6 weeks, that no new evidence of infection occurred during the 6 week treatment follow up.

    Effectiveness (performance) of the Silver II Non-Woven Dressing will be evaluated for efficacy success according to the following success criteria:

    Reduction in signs and symptoms of infection from baseline as defined as

    The change from the Investigator's opinion of infection being present to no longer being present, or If the Investigator determines infection is still present there is improvement in severity of at least two.

Secondary outcomes

  1. User satisfaction with the Silver II Non-Woven Dressing.

    Time frame: immediately following initial assessment, dressing removal every 7 days follow up visits, for 6 weeks.

    To establish clinician and user satisfaction Clinician satisfaction with the device (conformability & ease of use) this will be assessed using a Likert type scale. (Very satisfied, Satisfied and not Satisfied)

Sponsors and collaborators

Lead sponsor

Advanced Medical Solutions Ltd.

Industry

Collaborators

  • NAMSA

Registry information

Official study title

Post Market Surveillance Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Sep 16, 2021
Registry last updated
Nov 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.